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Genotype-Phenotype
Heterogeneity in Haemophilia
Muhammad Tariq Masood Khan and Abid Sohail Taj
Abstract
Haemophilia was previously regarded as a classical example of Mendelian
inheritance, with mutation in only a single gene (F8 or F9) causing the disease
phenotype. The disease manifests complete penetrance. Studies, however, revealed
the striking genetic and phenotypic heterogeneities of the disease. With further
sophistication of clinical and molecular techniques, the disease was also found to
have allele heterogeneity, phenotypic plasticity and variation in expressivity. The
variations are more pronounced in F9 variants with five distinct phenotypes. All
these phenomena advocate a rather complex genotype-phenotype relationship for
the disease. A keen insight into the matter may unveil new avenues of therapeutics.
Keywords: genotype-phenotype correlation, genotype-phenotype heterogeneity,
haemophilia
1. Phenotypic variation
1.1 Background
A phenotype is defined as an observable characteristic which is expressed by an
underlying genotype interacting with the environment [1]. Phenotype, in clinical
scenario, hence represents the observable interface of the disease in terms of clinical
features (laboratory findings, signs and symptoms) [2]. In contrast to genotype
which is a stable entity, phenotype is dynamic and influenced by both the genotype
and environment [3, 4]. Hence, in strict terms, the exact disease phenotype may be
difficult to ascertain in many cases. This uncertainty usually underlies contempo-
rary processes, directly or indirectly affecting the disease, with their own genetic
and/or environmental influences [2]. Precise definition for a specific phenotype,
therefore, needs development of a standardised comprehensive checklist of signs,
symptoms and laboratory findings [3]. This is considerably convenient in case of
monogenic disorders. Phenotypes for multigenic disorders or genetic diseases sig-
nificantly influenced by environmental interactions are difficult to delineate [5].
1.2 Phenotypic variation in haemophilia
Haemophilia is known to mankind since ancient times with references from
Babylonian history [6]. The first vague description of cases appeared in the tenth
century [7]. The first modern description of the disease was made in the eighteenth
1
century, and the term haemophilia was first used in 1828 by Johann Lukas Schönlein
and his student Friedrich Hopff [6].
The two diseases, haemophilia A (HA) and haemophilia B (HB), were initially
regarded as the same and attributed to fragility of vessels [8]. The idea later shifted
to abnormalities in platelets in the 1930s. It was in 1937, when Patek and Taylor
found the ‘anti-haemophilic globulin’, extracted from plasma, to be the factor
responsible. The two diseases were, however, first discriminated in 1944 by
Pavlosky of Buenos Aires [8].
In haemophilia, the phenotype is expressed at three distinct levels: the coagula-
tion activity, the factor antigen level and the clinical outcome in terms of bleeding
and its complications. Plasma procoagulant level, determined by coagulation activ-
ity, is the most important clinical entity determining severity of the disease.
Employing this parameter, the Scientific and Standardisation Committee classified
haemophilia A and haemophilia B into three major classes, that is, mild, moderate
and severe [9]. Each phenotype has a distinct clinical impact (Table 1). Patients
with severe phenotype (plasma factor level < 0.01 IU/ml; <1% of normal) com-
monly present with frequent (two to five bleeding episodes per month) spontane-
ous bleeding into the joints or deep muscles. Patients with moderate severity of the
disease (plasma factor level 0.01–0.05 IU/ml; 1–5% of normal) would bleed follow-
ing mild trauma; spontaneous bleeding is seen uncommonly. Diagnosis is usually
established in the first 5–6 years of life. Bleeding frequency ranges from once a
month to once a year. In mild severity of the disease (plasma factor level >0.05 to
<0.40 IU/ml; >5 to <40% of normal), bleeding occurs as a result of major trauma,
e.g., surgery or accident. Bleeding is infrequent in these patients [10, 11].
This is, however, noteworthy that patients with a specific severity of the disease
do not always behave as anticipated. Studies have reported a significant number of
severe haemophilia cases with a milder phenotype [1, 12, 13]. In such cases, bleed-
ing phenotype resembles that of moderate severity. These cases are hence treated
like moderate haemophilia; prophylactic treatment is often not needed.
2. Genetic heterogeneity in haemophilia
Haemophilia was previously regarded as a classical example of Mendelian
inheritance, with mutation in only one gene (F8 or F9) causing the disease pheno-
type. The concept, however, has significantly evolved in the last couple of decades,
and the two diseases are now recognised to have a heterogeneous spectrum of
mutations. More than 2800 mutations are reported in F8, whereas more than 1200
Severity FVIII:C/FIX:
C level (%)
Age at diagnosis Bleeding and haemarthroses
Severe ≤1 ≤2 years Spontaneous haemorrhages and haemarthroses since
early childhood
Moderate 2–5 <6 years Haemorrhage are usually secondary to minor trauma or
surgery; spontaneous haemarthrosis is unusual
Mild 6–40 Subject to
haemostatic
challenge
Haemorrhage secondary to surgery or major trauma;
spontaneous bleedings are rare
FVIII:C, factor VIII coagulation activity; FIX:C, factor IX coagulation activity.
Table 1.
Haemophilia severity classification on the basis of FVIII:C/FIX:C levels.
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mutations are reported in F9 [14]. These mutations, summarised in Table 2, include
all the major types of mutations. Point mutations are the most frequent, followed by
small indel mutations. Repeat variants are not yet reported to associate with the
disease. In majority of the cases, specific mutations result in the same disease
severity, a phenomenon referred to as genotype-phenotype correlation [13, 15].
2.1 Disease penetrance and expressivity
Penetrance refers to the appearance of disease in affected individuals, whereas
expressivity is the degree of severity of disease in patients [16]. Haemophilia is an
X-linked recessive genetic disorder with complete penetrance in most of the cases,
that is, male individuals with pathogenic variants in F8 or F9 are mostly fated to
have haemophilia. This stands true particularly in case of F8. Patients from the same
family have approximately the same severity status. However, the severity, as
described earlier, is not the same in all patients. Cases with the same mutations
exhibiting different levels of coagulation factor activity advocate variable expres-
sivity for the specific genotype. This variation is believed to be the outcome factors
including genetic alterations or polymorphisms in other genes (especially those
related to haemostasis, inflammation and immune response) and environmental
factors [17]. It has been established that the same genotype subjected to different
environments expresses diverse phenotypes [18]. This interaction between geno-
type and environment is called gene–environment interaction [19, 20].
Large structural changes in the protein, by default, tend to generate a severe
phenotype. Nonsense mutations, particularly those occurring in the early gene
segments, have a similar tendency. Almost all the nonsense mutations reported
within the initial part of the gene are associated with severe disease phenotype.
Frameshift mutations in F8/F9 gene are again usually associated with an adverse
phenotype [21].
Approximately 30% of the female individuals with heterozygous mutation have
a coagulation factor activity less than 40% [22]. Increased bleeding tendency among
the carriers, in comparison to normal females, is well documented [23, 24].
Mutation type F8 F9
Missense/nonsense 1674 748
Splicing 193 101
Regulatory 10 28
Small deletions 489 161
Small insertions 160 52
Small indels 38 17
Gross deletions 260 75
Gross insertions/duplications 40 7
Complex rearrangements 20 13
Repeat variations 0 0
Total 2884 1202
F8, factor VIII gene; F9, factor IX gene.
Table 2.
Frequency of different types of mutations reported in F8 and F9.
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In case of F9 sequence variants, besides classical HB, four other phenotypes are
reported. These are described in the following sections.
2.1.1 Haemophilia B Leyden
Haemophilia B Leyden is a specific type of HB in which the patient presents with
decreased FIX:C levels in the early childhood, but the levels progressively increase
after puberty. The disease is postulated to occur as a result of mutation in the 50 bp
region that spans the transcriptional start site [25]. A total of 23 promoter region
mutations have been identified until now (Table 3).
The mutation at c.-55G>C (or c. -26G>C in legacy nucleotide numbering) found
in the promoter region of F9 gene is also called the haemophilia B Brandenburg
mutation [38]. Unlike HB Leyden this variant does not exhibit improvement in FIX:
C levels with age. The promoter region sequence located at c.-34 to -10 of the F9
gene serves as a binding site for the hepatocyte nuclear factor 4 (HNF4). The liver-
enriched HNF4 is a member of the steroid hormone receptor superfamily of tran-
scription factors (also called the nuclear receptor superfamily). Mutation at HNF4
HGVS cDNA name Legacy nucleotide no. Nature of mutation Disease severity Reference
c.-55G>A -26 Substitution Moderate [26]
c.-55G>C -26 Substitution Severe [27]
c.-55G>T -26 Substitution Severe [28]
c.-53A>G -24 Substitution Not reported [21]
c.-52C>G -23 Substitution Not reported [21]
c.-52C>T -23 Substitution Not reported [29]
c.-50T>G -21 Substitution Not reported [30]
c.-49T>A -20 Substitution Moderate/mild [31]
c.-49T>C -20 Substitution Mild [32]
c.-48G>C -19 Substitution Moderate/mild [29]
c.-35G>A -6 Substitution Mild [33]
c.-35G>C -6 Substitution Mild [34]
c.-34A>G -5 Substitution Mild [26]
c.-34A>T -5 Substitution Moderate [35]
c.-24T>A 6 Substitution Mild [34]
c.-23T>C 7 Substitution Not reported [21]
c.-22T>C/c 8 Substitution Mild [36]
c.-22delT 8 Deletion Moderate [21]
c.-21C>G 9 Substitution Not reported [21]
c.-18A>G 12 Substitution Moderate [21]
c.-17A>C 13 Substitution Severe [26]
c.-17A>G 13 Substitution Mild [37]
c.-17delA 13 Deletion Mild [37]
HGVS, Human Genome Variation Society; no., number.
Table 3.
F9 promoter site mutations associated with HB Leyden (mutation c.-55G>C is an exception).
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disrupts the binding site to variable extents of severity. The mutation c.-55G>C,
however, occurs at a site which is overlapped by the HNF4 binding site and another
regulatory region, the androgen-responsive element (ARE) [39].
2.1.2 Thrombophilia
The F9 mutation c.1151G>T is associated with several fold increase in FIX:C
activity [40]. The mutant FIX has leucine substituted for arginine at p.Arg384Leu.
This alteration increases the affinity for FX to bind at this site. Patients might
present with thromboembolic complications. This variant was named ‘factor IX
Padua’. Studies have also demonstrated that Arg-338 is part of an exosite (a sec-
ondary binding site) that binds factor X and heparin at the same time [41].
People with FIX:C levels more than 129 U/dL are 2–3 times more at risk of
developing DVT in comparison to those with lower FIX:C levels. The risk is higher
in females [42]. Variations in F9-associated single-nucleotide polymorphisms
(SNPs) do not explain this raise in FIX antigen levels [43].
2.1.3 Protection against DVT
The Malmo polymorphism, c.580G>A (p. Ala194Thr), has an allele frequency of
0.32 in the Western population. It has been found that people with the G allele
(F9 Malmo) have a 15–43% decreased risk of developing DVT in comparison to
those with A allele [44]. This protective role of F9 Malmo has been extensively
studied and confirmed [45]. The biochemical mechanisms behind this phenomenon
are still obscure.
2.1.4 Warfarin sensitivity
All vitamin K-dependent clotting factors [including FII, FVII, FIX, FX, protein C
(PC), protein S (PS) and protein Z (PZ)] possess an 18 amino acid propeptide
sequence which serves as a binding site for the γ-glutamyl carboxylase enzyme. This
enzyme catalyses modification of certain glutamate residues in the amino terminus
of the mentioned clotting factors [46]. It has been determined that mutations at this
site reduce the affinity vitamin K-dependent γ-carboxylase for the proteins.
3. Phenotypic plasticity
Phenotypic plasticity is defined as ‘the ability of individual genotypes to produce
different phenotypes when exposed to different environmental conditions’ [47]. In
the current scenario, this refers to presentation of the same mutation with different
severities of the disease.
3.1 Genetic basis of phenotypic plasticity
It has been found that the mutations with varying phenotypes (MVPs) mostly
occur at the less conserved sites with Arg being the usual mutated residue. It is also
noted that these mutations commonly occur at the CpG dinucleotides. In compari-
son, mutations with uniform phenotypes (MUPs) occur in more conserved sites,
with cysteine as the most frequently mutated amino acid residue. Intrinsic protein
structural changes have been reported with reduced severity in cases of MVPs. No
significant structural variations are identified between the two groups. The phe-
nomenon is hypothesised to be a function of multiple factors including modifier
5
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1171C>T p.Arg391Cys Missense Substitution 8 a1 X X X
c.1172G>A p.Arg391His Missense Substitution 8 a1 X X X
c.1492G>A p.Gly498Arg Missense Substitution 10 A2 X X X
c.396A>C p.Glu132Asp Missense Substitution 4 A1 X X X
c.4380delT p.Asn1460Lysfs*5 Frameshift Deletion 14 B X X X
c.5122C>T p.Arg1708Cys Missense Substitution 14 a3 X X X
c.5219+3A>G Splice site change Substitution Intron 14 X X X
c.5399G>A p.Arg1800His Missense Substitution 16 A3 X X X
c.5663G>T p.Arg1888Ile Missense Substitution 17 A3 X X X
c.590T>G p.Val197Gly Missense Substitution 4 A1 X X X
c.6356A>G p.Gln2119Arg Missense Substitution 22 C1 X X X
c.6371A>G p.Tyr2124Cys Missense Substitution 22 C1 X X X
c.6506G>A p.Arg2169His Missense Substitution 23 C1 X X X
c.6545G>A p.Arg2182His Missense Substitution 23 C1 X X X
c.6683G>A p.Arg2228Gln Missense Substitution 24 C2 X X X
c.6977G>A p.Arg2326Gln Missense Substitution 26 C2 X X X
c.902G>A p.Arg301His Missense Substitution 7 A1 X X X
c.1063C>T p.Arg355* Nonsense Substitution 8 A1 X X
c.1226A>G p.Glu409Gly Missense Substitution 8 A2 X X
c.1316G>T p.Gly439Val Missense Substitution 9 A2 X X
c.143+1567A>G Splice site change Substitution Intron 1 X X
c.1475A>G p.Tyr492Cys Missense Substitution 10 A2 X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1639T>C p.Cys547Arg Missense Substitution 11 A2 X X
c.1702G>A p.Gly568Ser Missense Substitution 11 A2 X X
c.1754T>C p.Ile585Thr Missense Substitution 12 A2 X X
c.1804C>T p.Arg602* Nonsense Substitution 12 A2 X X
c.1809C>G p.Ser603Arg Missense Substitution 12 A2 X X
c.2015_2017del p.Phe672del Small structural change (in-frame, <50 bp) Deletion 13 A2 X X
c.2048A>G p.Tyr683Cys Missense Substitution 13 A2 X X
c.206_212del p.Leu69Glnfs*21 Frameshift Deletion 2 A1 X X
c.2090T>A p.Val697Asp Missense Substitution 13 A2 X X
c.2114-?_5219+?del Large structural change (>50 bp) Deletion 14 A3 X X
c.2159G>A p.Gly720Asp Missense Substitution 14 A2 X X
c.2182delT p.Ser728Leufs*23 Frameshift Deletion 14 A2 X X
c.2373G>A p.Trp791* Nonsense Substitution 14 B X X
c.2440C>T p.Arg814* Nonsense Substitution 14 B X X
c.266G>A p.Gly89Asp Missense Substitution 3 A1 X X
c.2945dupA p.Asn982Lysfs*9 Frameshift Duplication 14 B X X
c.296T>A p.Val99Asp Missense Substitution 3 A1 X X
c.3143G>A p.Trp1048* Nonsense Substitution 14 B X X
c.3300dupA p.Glu1101Argfs*17 Frameshift Duplication 14 B X X
c.353A>G p.His118Arg Missense Substitution 3 A1 X X
c.3637delA p.Ile1213Phefs*5 Frameshift Deletion 14 B X X
c.3637dupA p.Ile1213Asnfs*28 Frameshift Duplication 14 B X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.3702_3705del p.His1234Glnfs*2 Frameshift Deletion 14 B X X
c.388G>C p.Gly130Arg Missense Substitution 3 A1 X X
c.421G>A p.Glu141Lys Missense Substitution 4 A1 X X
c.4296_4300del p.His1434Serfs*6 Frameshift Deletion 14 B X X
c.4379dupA p.Asn1460Lysfs*2 Frameshift Duplication 14 B X X
c.43C>T p.Arg15* Nonsense Substitution 1 Signal X X
c.4796G>A p.Trp1599* Nonsense Substitution 14 B X X
c.4825dupA p.Thr1609Asnfs*4 Frameshift Duplication 14 B X X
c.491G>A p.Gly164Asp Missense Substitution 4 A1 X X
c.5113C>T p.Gln1705* Nonsense Substitution 14 a3 X X
c.515G>T p.Cys172Phe Missense Substitution 4 A1 X X
c.5219G>T p.Arg1740Met Missense Substitution 14 A3 X X
c.5471dupA p.Asn1824Lysfs*6 Frameshift Duplication 16 A3 X X
c.5536A>T p.Lys1846* Nonsense Substitution 16 A3 X X
c.556G>T p.Asp186Tyr Missense Substitution 4 A1 X X
c.5606G>T p.Gly1869Val Missense Substitution 17 A3 X X
c.5685delT p.Phe1895Leufs*50 Frameshift Deletion 17 A3 X X
c.5719A>T p.Ser1907Cys Missense Substitution 17 A3 X X
c.5878C>T p.Arg1960* Nonsense Substitution 18 A3 X X
c.5953C>T p.Arg1985* Nonsense Substitution 18 A3 X X
c.5973_5976del p.Met1992Hisfs*37 Frameshift Deletion 18 A3 X X
c.5998+1G>A Splice site change Substitution Intron 18 X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.5999-?_6429+?dup Large structural change (>50 bp) Duplication 19–22 X X
c.602-?_787+?del Large structural change (>50 bp) Deletion 5–6 X X
c.6046C>T p.Arg2016Trp Missense Substitution 19 A3 X X
c.6133G>A p.Gly2045Arg Missense Substitution 20 C1 X X
c.6172G>C p.Ala2058Pro Missense Substitution 20 C1 X X
c.6274-?_6429+?del Large structural change (>50 bp) Deletion 22 C1 X X
c.6403C>T p.Arg2135* Nonsense Substitution 22 C1 X X
c.6429+?_6430-?inv Large structural change (>50 bp) Inversion Intron 22 X X
c.6481C>T p.Pro2161Ser Missense Substitution 23 C1 X X
c.6485C>T p.Pro2162Leu Missense Substitution 23 C1 X X
c.6496C>T p.Arg2166* Nonsense Substitution 23 C1 X X
c.6544C>T p.Arg2182Cys Missense Substitution 23 C1 X X
c.6593G>T p.Gly2198Val Missense Substitution 24 C2 X X
c.6682C>G p.Arg2228Gly Missense Substitution 24 C2 X X
c.6682C>T p.Arg2228* Nonsense Substitution 24 C2 X X
c.670+5G>A Splice site change Substitution Intron 5 X X
c.6742T>A p.Trp2248Arg Missense Substitution 25 C2 X X
c.6875_6876del p.Phe2294Serfs*90 Frameshift Deletion 25 C2 X X
c.6967C>T p.Arg2323Cys Missense Substitution 26 C2 X X
c.6977G>T p.Arg2326Leu Missense Substitution 26 C2 X X
c.6994T>C p.Trp2332Arg Missense Substitution 26 C2 X X
c.764G>C p.Gly255Ala Missense Substitution 6 A1 X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.785C>T p.Pro262Leu Missense Substitution 6 A1 X X
c.787+3A>G Splice site change Substitution Intron 6 X X
c.822G>C p.Trp274Cys Missense Substitution 7 A1 X X
c.901C>T p.Arg301Cys Missense Substitution 7 A1 X X
c.954_955del p.Leu319Aspfs*18 Frameshift Deletion 7 A1 X X
c.991_992del p.Ile331Leufs*6 Frameshift Deletion 7 A1 X X
c.1043G>A p.Cys348Tyr Missense Substitution 8 A1 X X
c.121G>T p.Gly41Cys Missense Substitution 1 A1 X X
c.1409C>T p.Pro470Leu Missense Substitution 9 A2 X X
c.1751A>G p.Gln584Arg Missense Substitution 11 A2 X X
c.1910A>G p.Asn637Ser Missense Substitution 13 A2 X X
c.3870dupA p.Gly1291Argfs*29 Frameshift Duplication 14 B X X
c.437A>C p.Lys146Thr Missense Substitution 4 A1 X X
c.5150A>G p.Tyr1717Cys Missense Substitution 14 A3 X X
c.5183A>G p.Tyr1728Cys Missense Substitution 14 A3 X X
c.6273+1G>T Splice site change Substitution Intron 21 X X
c.677G>T p.Ser226Ile Missense Substitution 6 A1 X X
c.6967C>G p.Arg2323Gly Missense Substitution 26 C2 X X
c.902G>T p.Arg301Leu Missense Substitution 7 A1 X X
c.923C>T p.Ser308Leu Missense Substitution 7 A1 X X
c.1293G>T p.Leu431Phe Missense Substitution 9 A2 X X
c.1348T>A p.Tyr450Asn Missense Substitution 9 A2 X X
c.1408C>A p.Pro470Thr Missense Substitution 9 A2 X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1569G>T p.= Synonymous Substitution 11 A2 X X
c.1636C>T p.Arg546Trp Missense Substitution 11 A2 X X
c.1648C>T p.Arg550Cys Missense Substitution 11 A2 X X
c.1660A>G p.Ser554Gly Missense Substitution 11 A2 X X
c.1834C>T p.Arg612Cys Missense Substitution 12 A2 X X
c.2044G>T p.Val682Phe Missense Substitution 13 A2 X X
c.2149C>T p.Arg717Trp Missense Substitution 14 A2 X X
c.2167G>A p.Ala723Thr Missense Substitution 14 A2 X X
c.274G>A p.Gly92Ser Missense Substitution 3 A1 X X
c.311T>A p.Val104Asp Missense Substitution 3 A1 X X
c.410C>T p.Thr137Ile Missense Substitution 4 A1 X X
c.5096A>T p.Tyr1699Phe Missense Substitution 14 a3 X X
c.5143C>G p.Arg1715Gly Missense Substitution 14 A3 X X
c.5339C>A p.Pro1780Gln Missense Substitution 15 A3 X X
c.5393C>T p.Ala1798Val Missense Substitution 16 A3 X X
c.5398C>G p.Arg1800Gly Missense Substitution 16 A3 X X
c.541G>A p.Val181Met Missense Substitution 4 A1 X X
c.5428T>C p.Ser1810Pro Missense Substitution 16 A3 X X
c.5526G>A p.Met1842Ile Missense Substitution 16 A3 X X
c.5557G>A p.Ala1853Thr Missense Substitution 16 A3 X X
c.5618C>T p.Pro1873Leu Missense Substitution 17 A3 X X
c.5825G>C p.Gly1942Ala Missense Substitution 18 A3 X X
c.5879G>A p.Arg1960Gln Missense Substitution 18 A3 X X
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HGVS cDNA HGVS protein Mutation type Mechanism Exon Domain Severe (<1 U/dL) Moderate (1–5 U/dL) Mild (>5 U/dL)
c.5921C>T p.Ser1974Phe Missense Substitution 18 A3 X X
c.5954G>A p.Arg1985Gln Missense Substitution 18 A3 X X
c.601+1632G>A Splice site change Substitution Intron 4 X X
c.6113A>G p.Asn2038Ser Missense Substitution 19 A3 X X
c.6119G>A p.Cys2040Tyr Missense Substitution 20 C1 X X
c.6212G>C p.Arg2071Thr Missense Substitution 21 C1 X X
c.6278A>G p.Asp2093Gly Missense Substitution 22 C1 X X
c.6350T>G p.Ile2117Ser Missense Substitution 22 C1 X X
c.6413C>A p.Ser2138Tyr Missense Substitution 22 C1 X X
c.6443A>G p.Asn2148Ser Missense Substitution 23 C1 X X
c.6520C>G p.His2174Asp Missense Substitution 23 C1 X X
c.6532C>T p.Arg2178Cys Missense Substitution 23 C1 X X
c.668A>C p.Glu223Ala Missense Substitution 5 A1 X X
c.670+6T>C Splice site change Substitution Intron 5 X X
c.6744G>T p.Trp2248Cys Missense Substitution 25 C2 X X
c.67A>G p.Arg23Gly Missense Substitution 1 A1 X X
c.6915T>G p.Asn2305Lys Missense Substitution 26 C2 X X
c.6920A>C p.Asp2307Ala Missense Substitution 26 C2 X X
c.6956C>T p.Pro2319Leu Missense Substitution 26 C2 X X
c.755C>T p.Thr252Ile Missense Substitution 6 A1 X X
c.871G>A p.Glu291Lys Missense Substitution 7 A1 X X
Table 4.
List of F8 mutations reported with phenotypic plasticity.
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.87A>G p.Thr29Thr Synonymous Substitution 1 PRO X X X
c.127C>T p.Arg43Trp Missense Substitution 2 PRO X X X
c.128G>A p.Arg43Gln Missense Substitution 2 PRO X X X
c.172G>A p.Gly58Arg Missense Substitution 2 GLA X X X
c.173G>A p.Gly58Glu Missense Substitution 2 GLA X X X
c.191G>A p.Cys64Tyr Missense Substitution 2 GLA X X X
c.259T>G p.Phe87Val Missense Substitution 3 GLA X X X
c.301C>G p.Pro101Ala Missense Substitution 4 EGF1 X X X
c.316G>A p.Gly106Ser Missense Substitution 4 EGF1 X X X
c.412A>C p.Asn138His Missense Substitution 5 EGF2 X X X
c.415G>A p.Gly139Ser Missense Substitution 5 EGF2 X X X
c.571C>T p.Arg191Cys Missense Substitution 6 Linker X X X
c.572G>A p.Arg191His Missense Substitution 6 Linker X X X
c.720G>T p.Trp240Cys Missense Substitution 6 Protease X X X
c.755G>A p.Cys252Tyr Missense Substitution 7 Protease X X X
c.797C>T p.Ala266Val Missense Substitution 7 Protease X X X
c.835G>A p.Ala279Thr Missense Substitution 7 Protease X X X
c.838G>C p.Gly280Arg Missense Substitution 7 Protease X X X
c.881G>A p.Arg294Gln Missense Substitution 8 Protease X X X
c.914A>G p.Tyr305Cys Missense Substitution 8 Protease X X X
c.987C>G p.Ser329Arg Missense Substitution 8 Protease X X X
c.1009G>A p.Ala337Thr Missense Substitution 8 Protease X X X
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1025C>T p.Thr342Met Missense Substitution 8 Protease X X X
c.1135C>T p.Arg379* Nonsense Substitution 8 Protease X X X
c.1136G>A p.Arg379Gln Missense Substitution 8 Protease X X X
c.1187G>C p.Cys396Ser Missense Substitution 8 Protease X X X
c.1235G>A p.Gly412Glu Missense Substitution 8 Protease X X X
c.1240C>A p.Pro414Thr Missense Substitution 8 Protease X X X
c.1275A>C p.Leu425Phe Missense Substitution 8 Protease X X X
c.1304G>A p.Cys435Tyr Missense Substitution 8 Protease X X X
c.1306G>A p.Ala436Thr Missense Substitution 8 Protease X X X
c.1328T>C p.Ile443Thr Missense Substitution 8 Protease X X X
c.*2545A>G 30UTR Substitution 30UTR X X X
c.-17A>G Promoter Substitution 1 X X X
c.-35G>A Promoter Substitution 50UTR X X X
c.-35G>C Promoter Substitution 50UTR X X X
c.50T>A p.Ile17Asn Missense Substitution 1 Signal peptide X X
c.83G>A p.Cys28Tyr Missense Substitution 1 Signal peptide X X
c.128G>T p.Arg43Leu Missense Substitution 2 PRO X X
c.138G>T p.Arg47Ser Missense Substitution 2 PRO X X
c.190T>C p.Cys64Arg Missense Substitution 2 GLA X X
c.199G>A p.Glu67Lys Missense Substitution 2 GLA X X
c.219A>C p.Glu73Asp Missense Substitution 2 GLA X X
c.223C>T p.Arg75Stop Nonsense Substitution 2 GLA X X
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.226G>A p.Glu76Lys Missense Substitution 2 GLA X X
c.260T>G p.Phe87Cys Missense Substitution 3 GLA X X
c.263G>A p.Trp88* Nonsense Substitution 3 GLA X X
c.291T>G p.Cys97Trp Missense Substitution 4 EGF1 X X
c.304T>C p.Cys102Arg Missense Substitution 4 EGF1 X X
c.305G>A p.Cys102Tyr Missense Substitution 4 EGF1 X X
c.350G>A p.Cys117Tyr Missense Substitution 4 EGF1 X X
c.383G>A p.Cys128Tyr Missense Substitution 4 EGF1 X X
c.392delA p.Asp131fs Frameshift Deletion 5 EGF2 X X
c.414T>A p.Asn138Lys Missense Substitution 5 EGF2 X X
c.422G>A p.Cys141Tyr Missense Substitution 5 EGF2 X X
c.423C>A p.Cys141* Nonsense Substitution 5 EGF2 X X
c.423C>G p.Cys141Trp Missense Substitution 5 EGF2 X X
c.427C>G p.Gln143Glu Missense Substitution 5 EGF2 X X
c.434G>A p.Cys145Tyr Missense Substitution 5 EGF2 X X
c.464G>T p.Cys155Phe Missense Substitution 5 EGF2 X X
c.470G>A p.Cys157Tyr Missense Substitution 5 EGF2 X X
c.470G>C p.Cys157Ser Missense Substitution 5 EGF2 X X
c.479G>T p.Gly160Val Missense Substitution 5 EGF2 X X
c.482A>G p.Tyr161Cys Missense Substitution 5 EGF2 X X
c.484C>T p.Arg162* Nonsense Substitution 5 EGF2 X X
c.509G>A p.Ser170Tyr Missense Substitution 5 EGF2 X X
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.520G>A p.Val174Met Missense Substitution 5 EGF2 X X
c.532T>C p.Cys178Arg Missense Substitution 6 Linker X X
c.535G>A p.Gly179Arg Missense Substitution 6 Linker X X
c.545_546del p.Ser182Cysfs*6 Frameshift Deletion 6 Linker X X
c.547delG p.Val183fs Frameshift Deletion 6 Linker X X
c.676C>T p.Arg226Trp Missense Substitution 6 Activation X X
c.677G>A p.Arg226Gln Missense Substitution 6 Activation X X
c.677G>T p.Arg226Leu Missense Substitution 6 Activation X X
c.688_690del p.Gly230del Small structural change (in-frame, <50 bp) Deletion 6 Protease X X
c.706G>T p.Gly236Cys Missense Substitution 6 Protease X X
c.707G>A p.Gly236Asp Missense Substitution 6 Protease X X
c.711A>G p.Gln237Gln Synonymous Substitution 6 Protease X X
c.719G>A p.Trp240* Nonsense Substitution 6 Protease X X
c.719G>T p.Trp240Leu Missense Substitution 6 Protease X X
c.721C>T p.Gln241* Nonsense Substitution 6 Protease X X
c.723G>A p.Gln241Gln Synonymous Substitution 6 Protease X X
c.727_728delinsA p.Val243fs Frameshift Insertion/
deletion
7 Protease X X
c.757G>A p.Gly253Arg Missense Substitution 7 Protease X X
c.789_790InsT p.Thr264fs Frameshift Insertion 7 Protease X X
c.799C>T p.His267Tyr Missense Substitution 7 Protease X X
c.839G>T p.Gly280Val Missense Substitution 8 Protease X X
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(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.871G>A p.Glu291Lys Missense Substitution 8 Protease X X
c.880C>T p.Arg294* Nonsense Substitution 8 Protease X X
c.881G>T p.Arg294Leu Missense Substitution 8 Protease X X
c.892C>T p.Arg298* Nonsense Substitution 8 Protease X X
c.946A>T p.Ile316Phe Missense Substitution 8 Protease X X
c.990C>A p.Tyr330* Nonsense Substitution 8 Protease X X
c.1004G>T p.Cys335Tyr Missense Substitution 8 Protease X X
c.1009G>C p.Ala337Pro Missense Substitution 8 Protease X X
c.1068G>C p.Trp356Cys Missense Substitution 8 Protease X X
c.1069G>A p.Gly357Arg Missense Substitution 8 Protease X X
c.1070G>A p.Gly357Glu Missense Substitution 8 Protease X X
c.1076T>G p.Val359Gly Missense Substitution 8 Protease X X
c.1097C>A p.Ala366Asp Missense Substitution 8 Protease X X
c.1108C>T p.Gln370* Nonsense Substitution 8 Protease X X
c.1113C>A p.Tyr371* Nonsense Substitution 8 Protease X X
c.1120G>T p.Val374Glu Missense Substitution 8 Protease X X
c.1135C>G p.Arg379Gly Missense Substitution 8 Protease X X
c.1144T>C p.Cys382Arg Missense Substitution 8 Protease X X
c.1147C>T p.Leu383Phe Missense Substitution 8 Protease X X
c.1150C>T p.Arg384* Nonsense Substitution 8 Protease X X
c.1168A>T p.Ile390Phe Missense Substitution 8 Protease X X
c.1169T>G p.Ile390Ser Missense Substitution 8 Protease X X
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1181T>A p.Met394Lys Missense Substitution 8 Protease X X
c.1204G>A p.Gly402Arg Missense Substitution 8 Protease X X
c.1217C>G p.Ser406* Nonsense Substitution 8 Protease X X
c.1217C>T p.Ser406Leu Missense Substitution 8 Protease X X
c.1219T>C p.Cys407Arg Missense Substitution 8 Protease X X
c.1226G>A p.Gly409Glu Missense Substitution 8 Protease X X
c.1228G>A p.Asp410Asn Missense Substitution 8 Protease X X
c.1228G>C p.Asp410His Missense Substitution 8 Protease X X
c.1232G>A p.Ser411Asn Missense Substitution 8 Protease X X
c.1237G>A p.Gly413Arg Missense Substitution 8 Protease X X
c.1241C>T p.Pro414Leu Missense Substitution 8 Protease X X
c.1245T>A p.His415Gln Missense Substitution 8 Protease X X
c.1256T>A p.Val419Glu Missense Substitution 8 Protease X X
c.1258G>T p.Glu420* Nonsense Substitution 8 Protease X X
c.1291T>C p.Trp431Arg Missense Substitution 8 Protease X X
c.1293G>T p.Trp431Cys Missense Substitution 8 Protease X X
c.1294G>A p.Gly432Ser Missense Substitution 8 Protease X X
c.1295G>A p.Gly432Asp Missense Substitution 8 Protease X X
c.1295G>C p.Gly432Ala Missense Substitution 8 Protease X X
c.1295G>T p.Gly432Val Missense Substitution 8 Protease X X
c.1297G>A p.Glu433Lys Missense Substitution 8 Protease X X
c.1298A>C p.Glu433Ala Missense Substitution 8 Protease X X
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(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.1307C>T p.Ala436Val Missense Substitution 8 Protease X X
c.1318A>G p.Lys440Glu Missense Substitution 8 Protease X X
c.1324G>A p.Gly442Arg Missense Substitution 8 Protease X X
c.1357T>C p.Trp453Arg Missense Substitution 8 Protease X X
c.1361T>C p.Ile454Thr Missense Substitution 8 Protease X X
c.*1157A>G 30UTR Substitution 30UTR X X
c.252+3_252+6del Splice site change Deletion Intron 2 X X
c.252+6T>C Splice site change Substitution Intron 2 X X
c.253-25A>G Splice site change Substitution Intron 2 X X
c.277+2T>C Splice site change Substitution Intron 3 X X
c.277+5G>A Splice site change Substitution Intron 3 X X
c.392-1G>C Splice site change Substitution Intron 4 X X
c.392-2A>G Splice site change Substitution Intron 4 X X
c.521-3T>G Splice site change Substitution Intron 5 X X
c.-55G>A Promoter Substitution 50UTR X X
c.723+1G>A Splice site change Substitution Intron 6 X X
c.839-4A>G Splice site change Substitution Intron 7 X X
c.88+1_88+4del Splice site change Deletion Intron 1 X X
c.88+1G>T Splice site change Substitution Intron 1 X X
c.88+5G>C Splice site change Substitution Intron 1 X X
c.88+5G>T Splice site change Substitution Intron 1 X X
c.19A>T p.Ile7Phe Missense Substitution 1 Signal peptide X X
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HGVS cDNA name HGVS protein name Mutation type Mechanism Exon Domain Severe
(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.164T>G p.Phe55Cys Missense Substitution 2 GLA X X
c.339T>A p.Asn113Lys Missense Substitution 4 EGF1 X X
c.466T>C p.Ser156Phe Missense Substitution 5 EGF2 X X
c.676C>G p.Arg226Gly Missense Substitution 6 Activation X X
c.685G>A p.Gly229Ser Missense Substitution 6 Protease X X
c.907C>T p.His303Tyr Missense Substitution 8 Protease X X
c.942T>G p.His314Gln Missense Substitution 8 Protease X X
c.1045G>T p.Gly349* Nonsense Substitution 8 Protease X X
c.1072A>G p.Arg358Gly Missense Substitution 8 Protease X X
c.1079T>C p.Phe360Ser Missense Substitution 8 Protease X X
c.1109A>C p.Gln370Pro Missense Substitution 8 Protease X X
c.1174A>G p.Asn392Asp Missense Substitution 8 Protease X X
c.1238G>A p.Gly413Glu Missense Substitution 8 Protease X X
c.252+5G>A Splice site change Substitution Intron 2 X X
c.839-1G>A Splice site change Substitution Intron 7 X X
c.82T>C p.Cys28Arg Missense Substitution 1 Signal peptide X X
c.151A>G p.Lys51Glu Missense Substitution 2 GLA X X
c.163T>A p.Phe55Ile Missense Substitution 2 GLA X X
c.279T>A p.Asp93Glu Missense Substitution 4 EGF1 X X
c.335T>C p.Ile112Thr Missense Substitution 4 EGF1 X X
c.479G>A p.Gly160Glu Missense Substitution 5 EGF2 X X
c.479G>C p.Gly160Ala Missense Substitution 5 EGF2 X X
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(< 1 U/dL)
Moderate (1–5 U/dL) Mild (>5 U/dL)
c.484C>A p.Arg162Arg Synonymous Substitution 5 EGF2 X X
c.572G>C p.Arg191Pro Missense Substitution 6 Linker X X
c.785T>C p.Ile262Thr Missense Substitution 7 Protease X X
c.786T>G p.Ile262Met Missense Substitution 7 Protease X X
c.839G>C p.Gly280Ala Missense Substitution 8 Protease X X
c.872A>G p.Glu291Gly Missense Substitution 8 Protease X X
c.950C>T p.Ala317Val Missense Substitution 8 Protease X X
c.997C>A p.Pro333Thr Missense Substitution 8 Protease X X
c.1067G>T p.Trp356Leu Missense Substitution 8 Protease X X
c.1097C>T p.Ala366Val Missense Substitution 8 Protease X X
c.1127T>C p.Leu376Pro Missense Substitution 8 Protease X X
c.1180A>G p.Met394Val Missense Substitution 8 Protease X X
c.1187G>T p.Cys396Phe Missense Substitution 8 Protease X X
c.1193G>C p.Gly398Ala Missense Substitution 8 Protease X X
c.1348T>C p.Tyr450His Missense Substitution 8 Protease X X
c.-48G>C Promoter Substitution 50UTR X X
c.-49T>A Promoter Substitution 50UTR X X
c.520+13A>G Splice site change Substitution Intron 5 X X
c.88+5G>A Splice site change Substitution Intron 1 X X
Table 5.
List of F9 mutations reported with phenotypic plasticity.
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genes, epigenetic influences and environmental effects. These factors may act
individually or in combination [48].
Tables 4 and 5 depict F8 and F9 mutations, respectively, reported with pheno-
typic plasticity [49, 50]. A total of 351 mutations are presented here with cases
reported from at least two severity classes. The most significant are the 85 cases (32
from F8 and 53 from F9) wherein patients from both severe and mild categories are
reported.
Taking into account the significant amount of phenotypic plasticity in
haemophilia, researchers have proposed to recognise the disease phenotype, in
terms of coagulation activity, a continuous variable and abandoning of the classical
categorical classification [51]. With the evolving concepts of personalised medicine,
this may prove realistic… and the future.
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